ADMA Biologics (NASDAQ:ADMA) Issues Quarterly Earnings Results

ADMA Biologics (NASDAQ:ADMA) announced its earnings results on Wednesday. The biotechnology company reported $0.19 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.19, FiscalAI reports. The firm had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a return on equity of 38.94% and a net margin of 32.43%.The company’s revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.11 EPS.

Here are the key takeaways from ADMA Biologics’ conference call:

• Company reported strong profitability and cash generation in Q1 — adjusted net income rose 22% YoY, gross margin expanded to 71%, adjusted EBITDA was $59.7M, and operating cash flow was ~$58M with pro forma net leverage below 0.5x.
• ASCENIV is the operational growth engine with record demand and utilization (revenue +28% YoY), expanding prescriber adoption, and a recent pediatric label expansion that the company cites as a key catalyst.
• BIVIGAM sales fell ~54% YoY due to aggressive discounting from new entrants and distributor inventory/ordering shifts; management calls the disruption transitory but it materially pressured Q1 top line.
• Management narrowed visibility and withdrew longer-term guidance amid competitive uncertainty, setting 2026 revenue to $530M–$560M and raising near-term R&D/SG&A to support the pipeline, which could weigh on margins if competition persists.
• Pipeline progress — ADMA plans a Pre‑IND for SG‑001 this year, will present preclinical data soon, and estimates a potential $300M–$500M peak market while leveraging yield‑enhanced manufacturing and diversified plasma sourcing.

ADMA Biologics Price Performance

Shares of ADMA traded down $0.20 during midday trading on Friday, hitting $8.28. 2,893,139 shares of the company traded hands, compared to its average volume of 5,460,530. ADMA Biologics has a one year low of $7.21 and a one year high of $22.37. The firm has a market cap of $1.97 billion, a P/E ratio of 12.18 and a beta of 0.83. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The stock has a 50-day moving average of $12.12 and a 200-day moving average of $15.47.

Insider Activity at ADMA Biologics

In related news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the company’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the transaction, the chief operating officer directly owned 466,600 shares in the company, valued at approximately $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve Elms bought 7,000 shares of ADMA Biologics stock in a transaction that occurred on Thursday, March 5th. The stock was purchased at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the purchase, the director owned 2,038,730 shares of the company’s stock, valued at $31,946,899.10. The trade was a 0.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 3.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ADMA Biologics

Large investors have recently modified their holdings of the company. Janus Henderson Group PLC grew its stake in ADMA Biologics by 3,906.1% in the fourth quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock worth $71,820,000 after purchasing an additional 3,838,158 shares during the period. Caligan Partners LP bought a new position in shares of ADMA Biologics in the 3rd quarter worth about $38,653,000. Voloridge Investment Management LLC purchased a new position in ADMA Biologics during the 4th quarter valued at about $18,664,000. First Light Asset Management LLC purchased a new stake in ADMA Biologics in the second quarter worth about $17,338,000. Finally, Comerica Bank increased its stake in shares of ADMA Biologics by 821.9% during the third quarter. Comerica Bank now owns 772,634 shares of the biotechnology company’s stock valued at $11,327,000 after purchasing an additional 688,828 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ADMA has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Mizuho decreased their price objective on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday. Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday. Canaccord Genuity Group dropped their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Zacks Research downgraded shares of ADMA Biologics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, ADMA Biologics has an average rating of “Hold” and an average target price of $19.00.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ASCENIV growth and strong profitability: ASCENIV revenue rose ~28% year‑over‑year and helped drive solid margins and EPS improvement. ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Strong cash generation and adjusted profitability: Q1 adjusted net income and adjusted EBITDA increased year‑over‑year and cash from operations was ~$58M, supporting a healthy balance sheet. ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: EPS growth: GAAP/adjusted metrics showed year‑over‑year EPS improvement (Q1 EPS ~ $0.19 vs $0.11 a year ago), which supports near‑term profitability narrative. ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down (Zacks)
• Neutral Sentiment: Analyst actions: Mizuho trimmed its price target (from $24 to $20) but kept an outperform rating — reflects continued upside belief but reduced near‑term assumptions. Benzinga: Mizuho price target change
• Negative Sentiment: FY2026 guidance cut and withdrawal of long‑term guidance: ADMA updated FY2026 revenue guidance to $530M–$560M (well below Street ~ $625M) and withdrew longer‑term guidance, signaling near‑term market/competitive pressures in the immunoglobulin (IG) market. That outlook revision is a primary driver of the share decline. Adma projects 2026 revenue of $530M-$560M and withdraws longer-term guidance (Seeking Alpha)
• Negative Sentiment: Multiple securities investigations and channel‑stuffing allegations: Several law firms (Lowey Dannenberg, Bleichmar Fonti & Auld, Rosen, Pomerantz, Block & Leviton, Kehoe, etc.) have announced probes into ADMA following reports of channel‑stuffing and alleged misleading statements — this legal overhang amplifies selling pressure and uncertainty. Lowey Dannenberg investigation (GlobeNewswire) BFA investigation / channel‑stuffing claims (GlobeNewswire)
• Negative Sentiment: Large near‑term stock volatility: Media and law‑firm notices highlight a >20% intraday/overnight share drop after the call and guidance cut; increased volatility and potential litigation risk raise execution uncertainty for investors. Shares fall >24% (GlobeNewswire)

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.